Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Friend, Richard
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed
1/2
75
RoW
LASN01, Placebo
Lassen Therapeutics 1 PTY LTD
Pulmonary Fibrosis, Thyroid Eye Disease
11/24
11/24
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients

Recruiting
1/2
50
Europe, RoW
ADX-038, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Paroxysmal Nocturnal Hemoglobinuria (PNH)
03/26
09/26
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT05174013: Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Completed
1
32
RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
06/23
06/23
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Completed
1
90
RoW
AGA2118, Placebo
Angitia Biopharmaceuticals, Angitia Australia Pty Ltd
Osteoporosis
01/24
01/24
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Completed
1
31
RoW
TNB-738
TeneoFour Inc., Novotech (Australia) Pty Limited
Healthy Volunteer
05/23
07/23
AT02-001, NCT05521022: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Recruiting
1
100
US, RoW
AT-02, AT-02 (Placebo)
Attralus, Inc., Novotech (Australia) Pty Limited
Amyloidosis; Systemic
03/25
03/25
Boot, Kristoff
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Friend, Richard
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed
1/2
75
RoW
LASN01, Placebo
Lassen Therapeutics 1 PTY LTD
Pulmonary Fibrosis, Thyroid Eye Disease
11/24
11/24
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients

Recruiting
1/2
50
Europe, RoW
ADX-038, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Paroxysmal Nocturnal Hemoglobinuria (PNH)
03/26
09/26
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT05174013: Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Completed
1
32
RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
06/23
06/23
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Completed
1
90
RoW
AGA2118, Placebo
Angitia Biopharmaceuticals, Angitia Australia Pty Ltd
Osteoporosis
01/24
01/24
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Completed
1
31
RoW
TNB-738
TeneoFour Inc., Novotech (Australia) Pty Limited
Healthy Volunteer
05/23
07/23
AT02-001, NCT05521022: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Recruiting
1
100
US, RoW
AT-02, AT-02 (Placebo)
Attralus, Inc., Novotech (Australia) Pty Limited
Amyloidosis; Systemic
03/25
03/25
Boot, Kristoff
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24

Download Options